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Background: This study presents an analysis of 159 serotype 19A isolates from IPD in children before and after the
general recommendation for childhood pneumococcal conjugate vaccination in Germany in July 2006. Vaccination
formulations used were PCV7, PCV10 (from April 2009) and PCV13 (from Dec. 2009, replacing PCV7).
Methods: Isolates from invasive pneumococcal disease in children were serotyped using the Quellung reaction,
tested for antibiotic susceptibility and analysed for their multi locus sequence type.
Results: In an analysis of 3328 isolates from invasive pneumococcal disease (IPD) in children that were sent to the
German National Reference Center for Streptococci between July 1997 and June 2011, we show that the proportion of
19A isolates ranged between 1.7 and 4.2% in the period 1997 to 2006. After the recommendation for pneumococcal
conjugate childhood vaccination, which was issued in July 2006, the proportion of 19A isolates increased significantly
to 15.0% in 2010/11. Eight clonal complexes (CC) and groups accounted for 77.2% and 65.3% of all serotype 19A
isolates before and after vaccination, respectively. While three CCs and several STs were not detected after vaccine
introduction, four CCs and several STs first appeared after vaccination, including three ST320 isolates that could be
traced to recent imports from the US, UK and India. The proportion of penicillin-nonsusceptible and of
multidrug-resistant 19A isolates moderately increased after vaccine introduction. A significant increase in the use of
cephalosporins and azithromycin was noted post-vaccination (p=0.00001 and p=0.0013 respectively).
Conclusions: The prevalence of serotype 19A in Germany has increased significantly between July 2007 and June
2011. Possible reasons for this are the introduction of pneumococcal conjugate vaccination, increased use of
cephalosporins and azithromycin, import of multidrug-resistant isolates and increased reporting.
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Streptococcus pneumoniae remains a major cause of in-
fectious disease globally, especially in children. Invasive
pneumococcal disease (IPD) causes over 1 million deaths
among children worldwide [1]. The most important
virulence factor of S. pneumoniae is the polysaccharide
capsule. To date, 94 capsular types, or serotypes, have
been described.
Since 2001, a pneumococcal conjugate vaccine (PCV7)
has been available, covering the seven serotypes most* Correspondence: mlinden@ukaachen.de
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distribution, and reproduction in any mediumprevalent in invasive pneumococcal disease (4, 6B, 9 V,
14, 18C, 19 F and 23 F). In the US, a strong reduction in
the incidence of PCV7 vaccine serotype IPD has been
observed after a national immunization program (NIP)
with PCV7 began in 2000 [2]. This reduction was ac-
companied by an increase in IPD caused by non-PCV7
vaccine serotypes, however, it was to a much lower
extent than the reduction. The most prevalent of the
emerging non-PCV7 serotypes after vaccination in the
US was serotype 19A, and currently serotype 19A is the
most common serotype in IPD in children in the US [3]
also suggesting that antibodies to the serotype 19F poly-
saccharide, included in PCV7, do not offer cross-
protection against 19A infections.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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crease in serotype 19A infection was a direct result of
the vaccination program with PCV7 (‘serotype replace-
ment’) and if the phenomenon could be contributed
solely to vaccine use or whether other factors contribu-
ted to these changes in the serotype epidemiology. Even
though the majority of US post-NIP 19A still belong to
clonal complex (CC) 199, an increasing number of iso-
lates belong to a single multidrug-resistant (i.e. resistant
to more than 2 classes of antibiotics; MDR) clone,
ST320 [4-6]. It was therefore speculated that, among
several other factors, the increase could be a result of
selective pressure due to the excessive use of antibiotics.
Globally, inconsistent observations were made, e.g., an
increase of MDR clones of 19A has been observed
among IPD in children in Israel and in South Korea,
countries with very limited or no access to PCV7 at that
time [7-9].
In Europe, pneumococcal vaccination programs for
PCV7 have existed in most countries since 2006. Most of
these countries report a considerable reduction of vaccine
serotypes among IPD in children. However, many
European countries also report an increase in non-vaccine
serotype IPD, especially in serotype 19A [10-12].
The aim of the current study was to determine pos-
sible changes in the rate of reported infections and the
clonal composition of serotype 19A IPD isolates before
and after the widespread use of PCV7 in 2006 in
Germany, and to evaluate possible factors driving these
epidemiological changes, including PCV7 uptake and
antibiotic usage.
Methods
Study material
Serotype 19A isolates were obtained from an ongoing
surveillance study on IPD in German children under the
age of 16 from July 1997 to June 2011 [13]. This passive
laboratory surveillance system collects isolates from in-
vasive pneumococcal disease in children under 16 years
of age, from diagnostic laboratories all over Germany.
Participation of laboratories is voluntary. A nation-
wide active prospective hospital surveillance of IPD in
German pediatric hospitals is performed by the survey unit
for rare pediatric diseases in Germany (Erhebungseinheit
für Seltene Pädiatrische Erkrankungen in Deutschland,
ESPED) [14] and, together with the laboratory surveil-
lance system, allows for the calculation of IPD inci-
dences among German children, using capture recapture
between cases reported by hospitals and cases reported
by diagnostic laboratories [15,16]. Calculated incidences
indicate that for approximately half of the IPD cases, an
isolate is sent to the German National Reference Center.
S. pneumoniae isolated from blood, CSF or other
normally-sterile body sites were included in the study.Since pneumococcal infections appear to cluster around
the winter months, isolates are grouped according to
‘pneumococcal seasons’ (July in one year – June in the fol-
lowing year).
Pneumococcal vaccination
A recommendation for pneumococcal conjugate vacci-
nation for all children under 2 years of age was issued
by the German standing committee on vaccination
(STIKO) in July 2006. Germany does not have a national
immunization plan, but costs of recommended vacci-
nations are reimbursed by health insurance compa-
nies. A seven-valent pneumococcal conjugate vaccine
(PCV7, serotypes: 4, 6B, 9 V, 14, 18C, 19 F, 23 F) was
licensed in Germany in 2001, followed by PCV10
(serotypes PCV7 + 1, 5, 7 F) in April 2009 and PCV13
(serotypes PCV10 + 3, 6A, 19A) in December 2009
(replacing PCV7). The choice of vaccine is up to the
parents.
Serotyping
Pneumococcal isolates were serotyped by Neufeld’s
Quellung reaction using type and factor sera provided by
the Statens Serum Institut, Copenhagen, Denmark.
Susceptibility testing
All strains were tested for antibiotic minimal inhibitory
concentrations (MIC) using the broth microdilution
method as recommended by the CLSI [17]. The microti-
ter plates (Sensititre NLMMCS10, TREK Diagnostic Sys-
tems Ltd., East Grinstead, UK) contained penicillin
G, clarithromycin, clindamycin and tetracycline with ca-
tion adjusted Mueller-Hinton broth (Oxoid, Wesel,
Germany) and 5% lysed horse blood. The current CLSI
criteria were applied for interpretation [18]. To assess
the development of penicillin resistance and in the defi-
nition of multidrug resistance, the ‘oral’ penicillin break-
points were used (≤0.06 μg/ml, 0.12-1 μg/ml, ≥2 μg/ml),
since they give better insight into resistance develop-
ment over time. Otherwise, the parenteral breakpoints
(meningitis: ≤0.06 μg/ml, - , ≥0.12 μg/ml; non-meningi-
tis: ≤2 μg/ml, 4 μg/ml, ≥8 μg/ml) were used. Breakpoints
used for other antibiotics were: clarithromycin, clinda-
mycin: ≤0.25 μg/ml, 0.5 μg/ml, ≥1 μg/ml and tetracyc-
line: ≤2 μg/ml, 4 μg/ml, ≥8 μg/ml. Isolates were
considered multidrug-resistant when they were resistant
to more than two different classes of antibiotics.
Multilocus sequence typing
Multilocus sequence typing of selected pneumococcal
isolates was performed as described previously [19].
Briefly, internal fragments of the aroE, gdh, gki, recP, spi,
xpt, and ddl genes were amplified by PCR from chromo-
somal DNA with the described primer pairs. A special
Table 1 Isolates from IPD in children from Germany from July 1997 to June 2011, proportion of serotype 19A and
antibiotic resistance among serotype 19A isolates
Number
of
isolates
per
season
Number of
serotype
Number of 19A isolates resistant* (%)
Season 19A (%) PEN I+R CLA R CLI R TET R MDR
Pre-PCV vaccination period
1997-1998 167 7 (4.2) 1 (14.3) 1 (14.3) 0 (0.0) 1 (14.3) 0 (0.0)
1998-1999 152 6 (3.9) 2 (33.3) 1 (16.7) 1 (16.7) 1 (16.7) 1 (16.7)
1999-2000 190 6 (3.2) 1 (16.7) 2 (33.3) 2 (33.3) 3 (50.0) 2 (33.3)
2000-2001 238 5 (2.1) 0 (0.0) 1 (20.0) 1 (20.0) 1 (20.0) 1 (20.0)
2001-2002 241 7 (2.9) 3 (42.9) 1 (14.3) 1 (14.3) 2 (28.6) 1 (14.3)
2002-2003 239 4 (1.7) 0 (0.0) 1 (25.0) 1 (25.0) 0 (0.0) 1 (25.0)
2003-2004 272 6 (2.2) 2 (33.3) 1 (16.7) 1 (16.7) 1 (16.7) 0 (0.0)
2004-2005 286 11 (3.8) 5 (45.5) 4 (36.4) 3 (27.3) 5 (45.5) 2 (18.2)
2005-2006 291 6 (2.1) 2 (33.3) 2 (33.3) 1 (16.7) 4 (66.7) 1 (16.7)
Total 2076 58 (2.8#) 16 (27.6†) 14 (24.1) 11 (19.0) 18 (31.0) 9 (15.5)
Post-PCV vaccination period (PCV7)
2006-2007 295 12 (4.1) 3 (25.0) 5 (41.7) 5 (41.7) 6 (50.0) 5 (41.7)
2007-2008 241 11 (4.6) 4 (36.4) 2 (18.2) 1 (9.1) 4 (36.4) 1 (9.1)
2008-2009 249 19 (7.6) 12 (63.2) 5 (26.3) 4 (21.1) 8 (42.1) 5 (26.3)
Post-PCV vaccination period (PCV10, PCV7/13)
2009-2010 233 24 (10.3) 11 (45.8) 7 (29.2) 7 (29.2) 6 (25.0) 7 (29.2)
2010-2011 234 35 (15.0) 8 (22.9) 8 (22.9) 8 (22.9) 7 (20.0) 8 (22.9)
Total (post PCV) 1252 101 (9.9#) 38 (37.6†) 27 (26.7) 25 (24.8) 31 (30.7) 26 (25.7)
#The Fisher’s exact two-tailed P values are ≤0.001.
†The two-sampled t-test exact two-tailed P values are ≤0.05.
*PEN penicillin; CLA clarithromycin; CLI clindamycin; TET tetracycline; R resistant, I intermediately resistant'; MDR multidrug-resistant.
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seven loci and their sequence type (ST) is defined. The
allelic profiles were compared with each other and with
other isolates in the pneumococcal MLST database
using software available at www.mlst.net. Clusters of
related STs were grouped into clonal complexes (CCs)
using the program eBURST on the global database on
www.mlst.net.
Antibiotic and vaccine use
Data on vaccination rates are not publicly available in
Germany. Sales data for PCV7 and PCV13 were obtained
from Pfizer Pharma GmbH, Berlin, Germany. Yearly anti-
biotic sales data from the German health insurance
(Gesetzliche Krankenversicherung, GKV) database (dis-
pensed drugs based on analysis of all prescriptions) were
obtained from the scientific institute of the public health
insurances in Germany (Wissenschaftliches Institut der
AOK (Allgemeine Ortskrankenkassen), WidO), Berlin, a
central institute which summarizes national drug prescrip-
tion data for compulsory health insurances (90% of the
German population). The data were expressed in defineddaily doses (DDD) per 1,000 persons covered by the insu-
rance and day, using the Anatomical Therapeutic Chem-
ical (ATC) classification methodology and current DDD
definitions (www.whocc.no) – analogous to the DDD per
1,000 inhabitants and day format used in the European
Surveillance of Antibiotic Consumption (ESAC) project
(www.esac.ua.ac.be).
Statistical methods
Differences in proportions were tested by Fisher’s exact
test with a two-sided P value of <0.05 considered signifi-
cant. Differences in distributions were tested with a two-
sample t-test with P values of <0.05 considered significant.
Analyses were conducted using the Analysis Toolpak from
MS Excel and GraphPad (http://graphpad.com/quickcalcs/
contingency2).
Ethical statement
An ethical approval was not required since the study did
not involve human subjects, material or data.
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Figure 1 eBURST snapshot of 19A isolates from IPD in children in Germany before (black) and after (gray) the introduction of
pneumococcal conjugate vaccination. Circle size is proportional to the amount of isolates.
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From July 1997 until June 2011, a total of 3328 isolates
from invasive pneumococcal disease were sent to the
German National Reference Center for Streptococci. Iso-
late numbers varied from a minimum of 152 in 1998/99
to a maximum of 295 in 2006/07 (Table 1). The average
number of isolates per year was 238. Isolates were sent
in from all over Germany, with no geographical bias. A
total of 159 infections were caused by serotype 19A. The
percentage of serotype 19A isolates remained below 5%
until 2006, and then increased constantly over time, with
a significantly higher proportion (8.1%) during the post-
PCV-vaccination period when compared to the pre-
PCV-vaccination period (2.8%) (Table 1). Interestingly,
the stepwise introduction of higher-valent vaccines in
2009 only slightly reduced the increase in serotype 19A.
Forty-four 19A isolates (27.7%) were from patients with
meningitis. Among these, 15 isolates (34.1%) were resis-
tant to penicillin, according to the new (parenteral) CLSI
breakpoints (MIC ≥0.12 μg/ml) [17]. Penicillin resistance
rates post-vaccination were considerably higher (40.0%)than pre-vaccination (26.3%), though the difference was
not statistically significant (p=0.52). Among the 115 non-
meningitis isolates, only intermediate penicillin G resis-
tance (MIC=4 μg/ml) was found (4 cases, 3.5%).
As described in the materials and methods section, the
‘oral’ penicillin breakpoints (which correspond to the old
CLSI breakpoints [20]), were used to assess the develop-
ment of penicillin non-susceptibility among the 19A iso-
lates, since they give better insight into resistance
development over time. Applying these breakpoints, 54
isolates (9 resistant, 45 intermediately resistant) were
classified as penicillin non-susceptible (NS), and the pro-
portion of penicillin non-susceptible isolates increased
significantly (p=0.002) between the pre- and the post-
PCV-vaccination period (Table 1). Rates of resistance to
macrolides, clindamycin, and tetracycline were relatively
high, but did not change significantly over time (Table 1).
Seventy-five isolates were resistant to at least one, 59 to
at least two and 35 to three or more classes of antibio-
tics (using oral penicillin breakpoints). The latter isolates
were classified as multidrug-resistant (MDR) (Table 1).
Table 2 ST distribution among serotype 19A isolates from IPD in German children, before and after introduction of
pneumococcal conjugate vaccine
CC Before vaccination After vaccination
STs n= % STs n= % p-value
473 3301, 3344 2 3.5 0 0 0.1287
2699 2699 1 1.8 0 0 0.3608
3111 6968 1 1.8 0 0 0.3608
group of two (5480) 1565 1 1.8 0 0 0.3608
group of two (5954, 6967) 5954(3), 6967 4 7.0 0 0 0.0158
group of two (8025) 6970 1 1.8 0 0 0.3608
singleton 1587 1 1.8 0 0 0.3608
singleton 1546 1 1.8 0 0 0.3608
singleton 1007 1 1.8 0 0.0 0.3608
15 423(2), 1201(3), 3546, 6975 7 12.3 1201(3), 15 4 4.0 0.0582
63 1621(1+1) 2 3.5 63(3) 3 3.0 1.0000
156 165 1 1.8 172, 277(2), 1349 4 4.0 0.6545
177 193, 6966 2 3.5 193(3), 3863 4 4.0 1.0000
199 199(7), 416(5), 667(3), 1756(3) 18 31.6 199(10), 416(3+7), 667(4), 1756(5), 2220 30 29.7 0.5899
230 230(3), 276, 1611(5), 6969, 6974 11 19.3 276(2+2), 319(4), 1611(5), 2013(3), 6972, 6976 18 17.8 0.8329
432 1848(2) 2 3.5 1848(2) 2 2.0 0.6199
group of two (2668) 6973 1 1.8 6973 1 1.0 0.5358
81 0 81 1 1.0 1.0000
320 0 320(5), 2432, 3259 7 6.9 0.0496
733 0 733 1 1.0 1.0000
994 0 994(14), 4197, 6978 16 15.8 0.0006
group of two (2653) 0 482(6) 6 5.9 0.0880
singleton 0 5204(3) 3 3.0 0.5537
singleton 0 8031 1 1.0 1.0000
total 57 100 101 100
MDR isolates are indicated in bold. P-values from Fisher’s exact test, bold numbers are considered statistically significant (p<0.05).
van der Linden et al. BMC Infectious Diseases 2013, 13:70 Page 5 of 9
http://www.biomedcentral.com/1471-2334/13/70The proportion of isolates with resistance to at least one
drug and the proportion of MDR isolates also increased
moderately between the pre- and post-PCV-vaccination
period, but the differences were statistically not signifi-
cant (≥1 drug: p=0.7418, MDR: p=0.1655).
Multilocus sequence typing was performed for 158 of
the 159 isolates included in this study (one isolate could
not be regrown). The most common sequence types
found were ST199 (10.7%), ST416 (9.4%) and ST994
(8.8%) (Figure 1). When categorized according to clonal
complex (CC) CC199 was the most prevalent (30.4%),
followed by CC230 with 18.4%.
When the clonal composition of the serotype 19A iso-
lates before and after the start of the pneumococcal
conjugate vaccine recommendation in July 2006 was
compared, several changes in clonal composition could
be observed. Eight CCs or groups accounted for 77.2%
and 65.3% of all isolates before and after vaccination, re-
spectively. Three CCs and 7 other STs were not detectedafter vaccine introduction. Clonal complexes 81, 320,
733 and 994 and STs 482, 5204 and 8031 were detected
only after vaccine introduction. A significant prevalence
increase after the introduction of vaccination was only
detected for CC994 (p=0.0006) and CC320 (p= 0.0496)
(Table 2).
The increased proportion of MDR isolates was mainly
associated with increased proportions of CC230 and
CC320. Of note, in the period before vaccination, only
three MDR isolates with intermediate penicillin resis-
tance were found, all three belonging to CC230 (ST230).
After vaccination, 9 MDR isolates with high resistance
to penicillin were found, belonging to CC230 (ST276,
n=2), CC320 (ST320, n=5, ST2432, n=1) and CC81
(ST81, n=1) (Table 3). Three of the ST320 isolates
could be traced back to children that had recently
come to Germany. On the clinical data sheets sent in
with the isolates, it was stated that one child had
entered from the US shortly before being infected,
Table 3 MDR serotype 19A isolates from IPD in German children, before and after introduction of pneumococcal
conjugate vaccine
Date of Isolation Diagnosis Source CC ST PEN* (μg/ml) CLA* (μg/ml) CLI* (μg/ml) TET* (μg/ml)
Pre-vaccination
01.03.1999 CSF 230 230 0.25 32 32 32
09.09.1999 Blood 473 3344 0.03 32 32 32
27.01.2000 Blood 3111 6968 0.015 4 2 32
28.11.2000 Blood 63 1621 0.015 4 2 16
31.12.2001 Blood 230 230 0.12 32 32 16
01.01.2003 Blood n.d. n.d. 0.015 32 32 2
04.01.2005 Swab mastoid 230 230 0.25 32 32 32
07.01.2005 Blood 177 193 0.015 32 32 32
23.11.2005 Sepsis Blood 15 3546 0.015 32 32 32
Post-vaccination
29.09.2006 others Blood 432 1848 0.015 16 16 16
25.11.2006 Otitis media Blood 199 416 0.015 16 16 16
21.12.2006 Pneumonia Blood 230 276 2 16 16 16
08.01.2007 Meningitis CSF 177 193 0.015 16 16 16
08.06.2007 Pneumonia Pleuraempyema 177 193 0.015 16 16 16
20.10.2007 Sepsis Blood 177 193 0.015 16 16 16
05.11.2008 Pneumonia Blood 320 320 4 16 16 16
29.03.2009 Sepsis Blood 320 320 4 16 16 16
20.04.2009 Pleuritis Drainage thorax 320 2432 4 16 16 16
10.05.2009 Blood 81 81 2 8 0.5 16
29.06.2009 Blood 230 319 0.25 16 16 16
06.10.2009 Mastoiditis Swab mastoid 230 319 0.5 16 16 16
07.11.2009 Sepsis Blood 199 416 0.015 16 16 16
11.12.2009 Sepsis Blood 320 320 2 16 16 0.25
15.01.2010 Pneumonia Pleural fluid 320 320 2 16 16 16
23.02.2010 Blood 63 63 0.25 16 16 16
03.04.2010 Pneumonia Blood 432 1848 0.015 16 16 4
05.05.2010 Sepsis Blood 320 320 4 16 16 16
08.07.2010 Otitis media Blood 15 15 0.5 16 16 0.5
20.07.2010 CSF 63 63 0.12 16 16 16
16.09.2010 Phlegmon Blood 230 319 0.5 16 16 0.5
26.09.2010 Pneumonia Blood 230 276 2 16 4 16
28.12.2010 Blood 199 416 0.015 16 16 16
30.03.2011 Blood 63 63 0.06 16 16 16
13.04.2011 Meningitis CSF 177 3863 0.015 16 16 16
30.06.2011 Meningitis CSF 230 319 1 16 16 0.5
*PEN, penicillin; CLA, clarithromycin; CLI, clindamycin; TET, tetracycline.
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http://www.biomedcentral.com/1471-2334/13/70one from the UK, and a third had recently spent a
longer holiday in India. In fact these were the first,
second and third ST320, serotype 19A isolates ever
detected in Germany (Nov. 2008, Mar. 2009 and Dec.
2009, respectively). The only earlier detected ST320
isolate was a serotype 19F, found in June 2006. Theother two ST320 serotype 19A isolates (Jan. and May
2010), as well as the ST2432 isolate (Apr. 2009), had
no data which indicated a foreign origin.
Data on antibiotic use in Germany were available for
1997–2011. Significant increases in cephalosporin and
azithromycin use were noted when comparing the pre-
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respectively). However, with 23.4% of all macrolide use
in 2011, the proportional use of azithromycin remains
relatively low in Germany. Penicillin, macrolides (with-
out azithromycin) + clindamycin, and tetracycline use
increased incrementally, but did not show significant
change when comparing the pre- and post- vaccination
periods (Figure 2).
The number of marketed doses of PCV7 (since
2001) and PCV13 (since Dec. 2009) in Germany was
around 200,000 per year before the general vacci-
nation recommendation. After the recommendation
was issued in July 2006, this amount rose to an aver-
age of 2 million doses per year (Figure 2). The birth
cohorts in Germany have been an average 736,000
births/year from 1997–2006 and an average 675,000
births/year from 2007–2011.
Discussion
The general recommendation for childhood pneumococ-
cal conjugate vaccination was issued in Germany in July
2006, and full reimbursement of vaccination started in
January 2007. The uptake of the vaccine was estimated
to be almost 80% in 2007 [15] and is probably higher to
date. We were interested in evaluating the effects of vac-
cine introduction on the prevalence and clonal compo-
sition of serotype 19A among isolates from IPD in
German children <16 years of age.
An important limitation of our study was that the re-
ferral of isolates to the reference center was incomplete
since reporting IPD is not mandatory in Germany. How-
ever, reported cases show no regional bias, and referralpatterns have been constant for years. Using our
capture-recapture incidence calculations, we determined
that before the vaccination recommendation, a sample
had been sent to the National Reference Center for
40-50% of all IPD cases. This percentage increased to
50-60% after vaccination introduction [21]. Furthermore,
overall numbers of reported isolates have fallen since the
start of vaccination in 2006. Moreover, it should be
noted that these numbers include all cases in children
under 16 years of age, of which many are still unvacci-
nated. The number of cases in children under 2 years
of age has fallen more sharply: 2005–2006: 154,
2010–2011: 100.
The proportion of 19A isolates in Germany increased
significantly after vaccine introduction. However, an in-
crease in the incidence of infection due to serotype 19A
(as calculated using capture-recapture) was observed only
in 2008/2009 [22], but not in 2007/2008 [15]. Therefore,
the increased proportion of 19A isolates in the first two
seasons following the vaccination recommendation could
have been due to increased reporting [21]. Additionally,
the increasing use of cephalosporins and perhaps of azi-
thromycin in the general population may have been a fac-
tor in the change in 19A epidemiology, including the
increased proportion of resistant 19A isolates. The in-
crease in serotype 19A was only slightly affected by the
introduction of higher-valent vaccines in Germany. A rea-
son for this could be that PCV13 was only introduced in
December 2009, and it is too early to see more clear
effects in the 2010–2011 pneumococcal season. However,
when the 19A prevalence data are grouped by calendar
year (Figure 2) an indication for a decrease is observed.
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http://www.biomedcentral.com/1471-2334/13/70In the US, an increase in 19A was reported among
Alaskan children [23], as well as in the general child-
hood population [4]. Richter et al. reported most of the
penicillin-resistant and multidrug-resistant isolates after
vaccination to have serotype 19A [24]. Spain and France
also report increases in 19A after the start of vaccination
programs [10,12]. However, reports from South Korea,
Belgium and Israel show an increase in serotype 19A
isolates from IPD in children before the introduction of
pneumococcal conjugate vaccination [7,8,11]. Therefore,
the increase in 19A is unlikely to be caused only by
vaccination.
Despite the increases in cephalosporin and azithromy-
cin use reported here, antibiotic prescription rates in
Germany are generally low. Therefore, the selective ad-
vantage in carriage for resistant isolates, like MDR 19A,
will be lower. This might be the reason why these clones
do not (yet) persist in Germany. The only MDR 19A iso-
lates reported before introduction of the vaccine belonged
to CC230 (ST230), a more common clone in Germany,
which also persists post-vaccination (ST319, ST276).
However, these isolates show a considerably lower MIC
for penicillin. MDR 19A ST320 isolates have also been
reported from Spain and Italy, and MDR 19F ST320
isolates from Poland (http://spneumoniae.mlst.net/).
All of the observed STs in this study have been corre-
lated to serotype 19A or 19F before. (www.mlst.net).
Moore et al., Beall et al. and Pillai et al. have described
ST320 as the most prevalent multi-drug-resistant sero-
type 19A clone in the US and in Canada, respectively
[4,6,25]. Of the newly-appeared STs after vaccination
start in Germany, seven were MDR, of which six
belonged to CC320. Interestingly, three of these isolates
(all ST320) were from children that had recently come
to Germany from abroad. Moreover, these were the first
three ST320, serotype 19A isolates ever detected among
children with IPD in Germany. This shows that at least
some of the MDR 19A isolates that appeared after intro-
duction of the vaccine in Germany are recent imports
from countries where antibiotic pressure is higher than
in Germany.
Still, a majority of the post-vaccination serotype 19A
isolates are drug-susceptible and belong to the same
clonal complexes as pre-vaccination 19A isolates. This
shows that the main burden of serotype 19A is caused
by the expansion of existing clones, although the fact
that CCs 320 and 994 were detected significantly more
often after vaccination introduction could indicate that a
shift in the population of serotype 19A pneumococci in
Germany is at hand. In a study on pneumococcal car-
riage in children in Massachusetts, Hanage et al. found
that the most common serotype 19A clonal complex
before and after vaccination was CC199 and that the
observed increase was due to ST320 and ST695 [26].Relatedly, in a recent paper from Portugal, Aguiar et al.
show that the increase in 19A after the start of vacci-
nation is due to an expansion of existing lineages
(CC230) that are MDR [27]. They did not find any
CC320 isolates.
After the issue of the general recommendation for
pneumococcal vaccination in July 2006, the amount of
sold doses of PCV7 rose strongly from 200,000 to 2 mil-
lion per year (Figure 2). The increased use of the vaccine
will have reduced carriage of 7-valent vaccine serotypes
among children, thereby creating a niche for other sero-
types. A study in the Netherlands showed increased
carriage of serotype 19A in vaccinated children as com-
pared with unvaccinated controls [28].
Our analysis shows that, after the start of pneumococ-
cal conjugate vaccination in Germany, the epidemio-
logy of serotype 19A in invasive pneumococcal disease
among children has changed. Even though the majority
of the clones has remained the same, several STs were
not detected after the start of vaccination, while other
STs were only detected after vaccination had started.
Among these newly-detected STs are a number of MDR
isolates, with high penicillin resistance.Conclusion
The increase in serotype 19A IPD isolates seems to be
related to several factors. Increased awareness may have
led to a higher amount of reported isolates. The
extended use of PCV7 has potentially created a niche in
carriage, which may have been occupied by 19A. The
three first MDR 19A (ST320) isolates detected among
children with IPD in Germany were shown to be
imported from countries with a relatively high antibiotic
pressure. Increasing use of cephalosporins and azithro-
mycin might have favored the selection and/or expan-
sion of penicillin-non-susceptible 19A clones.
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